Clinical trials: Leucogen
Nasopharyngeal Carcinoma (NPC)
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune…
- Trial name
- NCT06676293
- Testing
- Anti-PD1, asparaginase
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Chang Gung Memorial Hospital
Leukemia
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005914
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Relapse Leukemia
Outcome Following Truncation of Asparaginase
This study aimed to investigate the outcome of patients who had their asparaginase treatment truncated in the NOPHO ALL2008 protocol.
- Trial name
- NCT03987542
- Where
- Denmark
- Volunteers
- 1,401 people
- Sponsor
- Birgitte Klug Albertsen
Acute Lymphoid Leukemia
Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
This non-controlled multicentre phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase (rASNase) for first-line treatment of infants (< 1…
- Trial name
- NCT00983138
- Testing
- recombinant asparaginase
- Where
- 17 sites in Germany, Netherlands
- Volunteers
- 12 people
- Sponsor
- medac GmbH
Acute Lymphoblastic Leukemia
Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
Early Access Program to provide L-asparaginase encapsulated in Erythrocyte (GRASPA®) for patient unable to receive any other form of Asparaginase.
- Trial name
- EAP (NCT02197650)
- Testing
- suspension of erythrocytes encapsulating L-asparaginase
- Where
- 10 sites in France
- Sponsor
- ERYtech Pharma
Extranodal NK/T-cell Lymphoma, Nasal Type
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.
- Trial name
- NCT02631239
- Testing
- Methotrexate, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Ruijin Hospital
Acute T Cell Leukemia
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute…
- Trial name
- NCT03613428
- Testing
- Ruxolitinib, Vincristine, Prednisone
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Acute Lymphoblastic Leukemia
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Evaluation of the association between risk and severity of asparaginase associated toxicities and asparaginase enzyme activity levels in children with Acute Lymphoblastic Leukemia treated in the NOPHO-ALL 2008 protocol.
- Trial name
- NCT04187248
- Testing
- Asparaginase
- Where
- Denmark
- Volunteers
- 1,248 people
- Sponsor
- Aarhus University Hospital
Acute Lymphoblastic Leukemia
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
The main purpose of this study is to determine the maximum tolerated and efficient dose of GRASPA® in combination with polychemotherapy treatment of elderly patients with ALL, 55 years and over, Philadelphia chromosome-negative…
- Trial name
- NCT01523782
- Testing
- GRASPA
- Volunteers
- 30 people
- Sponsor
- ERYtech Pharma
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of…
- Trial name
- NCT07221656
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Survival rates exceed 90% in children and 75% in adults (aged 18-45 years).
- Trial name
- NCT04843150
- Where
- 2 sites in Denmark
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Lymphoma, Extranodal NK-T-Cell
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.
- Trial name
- NCT03154918
- Testing
- GLIDE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan University
Lymphoma
New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of L-asparaginase plus DICE regimen in the patients with early stage NK/T-cell lymphoma.
- Trial name
- NCT00933673
- Testing
- L-asp, DXM, IFO, VP-16, DDP
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Leukemia, Lymphoma
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00882206
- Testing
- cytarabine, decitabine, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
- Trial name
- NCT06600659
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
This study is an Expanded Access Protocol (EAP) of JZP458 in participants with ALL/LBL who are hypersensitive to an E.coli-derived asparaginase (allergic reaction or silent inactivation) and unable to access alternative licensed…
- Trial name
- NCT04943952
- Testing
- Asparaginase Erwinia Chrysanthemi (recombinant)
- Sponsor
- Jazz Pharmaceuticals
Acute Lymphoblastic Leukemia
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
The goal of this study is to find a safe dose of sirolimus that can be used with a standard dose of L-asparaginase. To find the safe dose, the investigators will give the first patient a very small dose of sirolimus (smaller than…
- Trial name
- NCT00957320
- Testing
- Sirolimus, PEG-asparaginase
- Where
- United States
- Sponsor
- Emory University
Acute Myeloid Leukemia
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
Erwinaze will be administered intravenously at a dose of 25,000 IU/m2 (dose cohort 0) for 6 doses MWF over a period of 2 weeks to 9 patients (as described below and in the following schema).
- Trial name
- NCT02283190
- Testing
- Erwinase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ashkan Emadi
Acute Lymphoblastic Leukemia
Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia
The aim of this study is to optimize target trough attainment while minimizing high exposures that impose increased risk of side effects such as hyperammonemia.
- Trial name
- NCT07499349
- Testing
- Erwinase PK-model for children and young adults with ALL
- Where
- Denmark
- Volunteers
- 475 people
- Sponsor
- Aarhus University Hospital